News & Updates

Once-daily treatment with sustained-release (SR) ivabradine hemisulfate, alongside optimum standard therapy, results in better heart function in patients with chronic heart failure with reduced ejection fraction (HFrEF), reports a study.

Treatment with angiotensin receptor blockers (ARBs) appears to reduce the risk of Parkinson’s disease (PD) in patients newly diagnosed with hypertension, reports a recent study.

The long-acting combination of cabotegravir plus rilpivirine, administered as monthly or once-every-2-months jabs, appears to be effective in both older and younger patients living with HIV, with most maintaining virologic suppression through week 96, according to pooled data from the phase III ATLAS, FLAIR, and ATLAS-2M studies.

For mothers with hepatitis B virus (HBV) infection who are positive for both hepatitis B surface and envelope antigens, administering a combination of hepatitis B vaccine and immunoglobulin (HBIG) in their infants plus tenofovir disoproxil fumarate (TDF) in the mothers themselves appears to be the best approach for preventing vertical disease transmission, according to a study.

The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.